Serum concentrations of aminoterminal propeptide of type III procollagen and propeptide of human type I procollagen in systemic lupus erythematosus

A. I. Villa-Manzano; J. I. Gamez-Nava; M. Salazar-Paramo; I. C. Valera-Gonzalez; A. Garcia-Gonzalez; G. Garcia-Gonzalez; J. Morales-Romero; A. Lopez-Olivo; L. M. Galvan-Ramirez; R. Ruiz-Ruvalcaba; E. G. Cardona-Muñoz; L. Gonzalez-Lopez

doi:10.1007/s00296-005-0064-5

Serum concentrations of aminoterminal propeptide of type III procollagen and propeptide of human type I procollagen in systemic lupus erythematosus

A. I. Villa-Manzano, J. I. Gamez-Nava, M. Salazar-Paramo, I. C. Valera-Gonzalez, A. Garcia-Gonzalez, G. Garcia-Gonzalez, J. Morales-Romero, A. Lopez-Olivo, L. M. Galvan-Ramirez, R. Ruiz-Ruvalcaba, E. G. Cardona-Muñoz, L. Gonzalez-Lopez

Research output: Contribution to journal › Article › peer-review

Abstract

The purpose of this study was to assess the association between the serum levels of aminoterminal propeptide of type III procollagen (PIIINP) and carboxyterminal propeptide of type I procollagen (PICP) with disease activity and damage in systemic lupus erythematosus (SLE). Thirty-three patients with SLE were compared with 31 controls. The assessment in SLE included disease activity indices (SLEDAI, MEX-SLEDAI) and damage index (SLICC/ACR). PIIINP and PICP were measured by radioimmunoassay. Compared with controls, mean levels of PIIINP were higher in SLE (2.9 ± 1.8 vs. 1.8 ± 1.2, P = 0.006). PICP was also increased in SLE versus controls (163 ± 94 vs. 102 ± 62, P = 0.007). PIIINP was correlated with SLICC/ACR (r = 0.33, P = 0.048). No correlation was observed between PICP and PIIINP with other clinical or therapeutic variables. These preliminary data suggests a role of PIIINP as a marker for chronic damage. Follow-up studies are required to evaluate its utility in predicting future damage.

Original language	English (US)
Pages (from-to)	712-716
Number of pages	5
Journal	Rheumatology International
Volume	26
Issue number	8
DOIs	https://doi.org/10.1007/s00296-005-0064-5
State	Published - Jun 2006
Externally published	Yes

Keywords

Damage
PICP
PIIINP
SLE
SLICC/ACR

ASJC Scopus subject areas

Immunology and Allergy
Rheumatology
Immunology

Access to Document

10.1007/s00296-005-0064-5

Cite this

Villa-Manzano, A. I., Gamez-Nava, J. I., Salazar-Paramo, M., Valera-Gonzalez, I. C., Garcia-Gonzalez, A., Garcia-Gonzalez, G., Morales-Romero, J., Lopez-Olivo, A., Galvan-Ramirez, L. M., Ruiz-Ruvalcaba, R., Cardona-Muñoz, E. G., & Gonzalez-Lopez, L. (2006). Serum concentrations of aminoterminal propeptide of type III procollagen and propeptide of human type I procollagen in systemic lupus erythematosus. Rheumatology International, 26(8), 712-716. https://doi.org/10.1007/s00296-005-0064-5

Villa-Manzano, AI, Gamez-Nava, JI, Salazar-Paramo, M, Valera-Gonzalez, IC, Garcia-Gonzalez, A, Garcia-Gonzalez, G, Morales-Romero, J, Lopez-Olivo, A, Galvan-Ramirez, LM, Ruiz-Ruvalcaba, R, Cardona-Muñoz, EG & Gonzalez-Lopez, L 2006, 'Serum concentrations of aminoterminal propeptide of type III procollagen and propeptide of human type I procollagen in systemic lupus erythematosus', Rheumatology International, vol. 26, no. 8, pp. 712-716. https://doi.org/10.1007/s00296-005-0064-5

@article{5640bd08f85f4db8bd2a49d938dd1f07,

title = "Serum concentrations of aminoterminal propeptide of type III procollagen and propeptide of human type I procollagen in systemic lupus erythematosus",

abstract = "The purpose of this study was to assess the association between the serum levels of aminoterminal propeptide of type III procollagen (PIIINP) and carboxyterminal propeptide of type I procollagen (PICP) with disease activity and damage in systemic lupus erythematosus (SLE). Thirty-three patients with SLE were compared with 31 controls. The assessment in SLE included disease activity indices (SLEDAI, MEX-SLEDAI) and damage index (SLICC/ACR). PIIINP and PICP were measured by radioimmunoassay. Compared with controls, mean levels of PIIINP were higher in SLE (2.9 ± 1.8 vs. 1.8 ± 1.2, P = 0.006). PICP was also increased in SLE versus controls (163 ± 94 vs. 102 ± 62, P = 0.007). PIIINP was correlated with SLICC/ACR (r = 0.33, P = 0.048). No correlation was observed between PICP and PIIINP with other clinical or therapeutic variables. These preliminary data suggests a role of PIIINP as a marker for chronic damage. Follow-up studies are required to evaluate its utility in predicting future damage.",

keywords = "Damage, PICP, PIIINP, SLE, SLICC/ACR",

author = "Villa-Manzano, {A. I.} and Gamez-Nava, {J. I.} and M. Salazar-Paramo and Valera-Gonzalez, {I. C.} and A. Garcia-Gonzalez and G. Garcia-Gonzalez and J. Morales-Romero and A. Lopez-Olivo and Galvan-Ramirez, {L. M.} and R. Ruiz-Ruvalcaba and Cardona-Mu{\~n}oz, {E. G.} and L. Gonzalez-Lopez",

note = "Funding Information: Acknowledgments Grants: The study was supported by Funding of CONACyT Mexico. Grants: 20000302009 and MICH-2003-C01-12442 and by the IMSS-FOFOI FP:0038/1219.",

year = "2006",

month = jun,

doi = "10.1007/s00296-005-0064-5",

language = "English (US)",

volume = "26",

pages = "712--716",

journal = "Rheumatology International",

issn = "0172-8172",

publisher = "Springer Verlag",

number = "8",

}

TY - JOUR

T1 - Serum concentrations of aminoterminal propeptide of type III procollagen and propeptide of human type I procollagen in systemic lupus erythematosus

AU - Villa-Manzano, A. I.

AU - Gamez-Nava, J. I.

AU - Salazar-Paramo, M.

AU - Valera-Gonzalez, I. C.

AU - Garcia-Gonzalez, A.

AU - Garcia-Gonzalez, G.

AU - Morales-Romero, J.

AU - Lopez-Olivo, A.

AU - Galvan-Ramirez, L. M.

AU - Ruiz-Ruvalcaba, R.

AU - Cardona-Muñoz, E. G.

AU - Gonzalez-Lopez, L.

N1 - Funding Information: Acknowledgments Grants: The study was supported by Funding of CONACyT Mexico. Grants: 20000302009 and MICH-2003-C01-12442 and by the IMSS-FOFOI FP:0038/1219.

PY - 2006/6

Y1 - 2006/6

N2 - The purpose of this study was to assess the association between the serum levels of aminoterminal propeptide of type III procollagen (PIIINP) and carboxyterminal propeptide of type I procollagen (PICP) with disease activity and damage in systemic lupus erythematosus (SLE). Thirty-three patients with SLE were compared with 31 controls. The assessment in SLE included disease activity indices (SLEDAI, MEX-SLEDAI) and damage index (SLICC/ACR). PIIINP and PICP were measured by radioimmunoassay. Compared with controls, mean levels of PIIINP were higher in SLE (2.9 ± 1.8 vs. 1.8 ± 1.2, P = 0.006). PICP was also increased in SLE versus controls (163 ± 94 vs. 102 ± 62, P = 0.007). PIIINP was correlated with SLICC/ACR (r = 0.33, P = 0.048). No correlation was observed between PICP and PIIINP with other clinical or therapeutic variables. These preliminary data suggests a role of PIIINP as a marker for chronic damage. Follow-up studies are required to evaluate its utility in predicting future damage.

AB - The purpose of this study was to assess the association between the serum levels of aminoterminal propeptide of type III procollagen (PIIINP) and carboxyterminal propeptide of type I procollagen (PICP) with disease activity and damage in systemic lupus erythematosus (SLE). Thirty-three patients with SLE were compared with 31 controls. The assessment in SLE included disease activity indices (SLEDAI, MEX-SLEDAI) and damage index (SLICC/ACR). PIIINP and PICP were measured by radioimmunoassay. Compared with controls, mean levels of PIIINP were higher in SLE (2.9 ± 1.8 vs. 1.8 ± 1.2, P = 0.006). PICP was also increased in SLE versus controls (163 ± 94 vs. 102 ± 62, P = 0.007). PIIINP was correlated with SLICC/ACR (r = 0.33, P = 0.048). No correlation was observed between PICP and PIIINP with other clinical or therapeutic variables. These preliminary data suggests a role of PIIINP as a marker for chronic damage. Follow-up studies are required to evaluate its utility in predicting future damage.

KW - Damage

KW - PICP

KW - PIIINP

KW - SLE

KW - SLICC/ACR

UR - http://www.scopus.com/inward/record.url?scp=33646574292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646574292&partnerID=8YFLogxK

U2 - 10.1007/s00296-005-0064-5

DO - 10.1007/s00296-005-0064-5

M3 - Article

C2 - 16231121

AN - SCOPUS:33646574292

SN - 0172-8172

VL - 26

SP - 712

EP - 716

JO - Rheumatology International

JF - Rheumatology International

IS - 8

ER -

Serum concentrations of aminoterminal propeptide of type III procollagen and propeptide of human type I procollagen in systemic lupus erythematosus

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this